BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29102081)

  • 1. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
    Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
    Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
    Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
    Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
    Wang L; Ai M; Yu J; Jin L; Wang C; Liu Z; Shu X; Tang Z; Liu K; Luo H; Guan W; Sun X; Ma X
    Eur J Med Chem; 2019 Jun; 172():154-162. PubMed ID: 30978560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
    Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
    Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H; Lin X; Zhang Y; Tan F; Chi B; Peng Z; Dong W; An D
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127459. PubMed ID: 32784087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH; Mohamed MS; Ragb EA
    Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.
    Ai M; Wang C; Tang Z; Liu K; Sun X; Ma T; Li Y; Ma X; Li L; Chen L
    Bioorg Chem; 2020 Jan; 94():103408. PubMed ID: 31706682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
    Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.
    Wei W; Feng Z; Liu Z; Li X; He H; Ran K; Shi Y; Zhu Y; Ye T; Gao C; Wang N; Yu L
    Eur J Med Chem; 2022 Jan; 228():113978. PubMed ID: 34810020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
    Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
    Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
    Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
    Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
    Duan YT; Yao YF; Huang W; Makawana JA; Teraiya SB; Thumar NJ; Tang DJ; Tao XX; Wang ZC; Jiang AQ; Zhu HL
    Bioorg Med Chem; 2014 Jun; 22(11):2947-54. PubMed ID: 24792811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
    Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
    Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.